Back to Results

Pan Optica

Title A Phase 1, Open-Label, Multi-Center Trial with Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD)
Therapeutic Area Macular Degeneration, Ophthalmology
Principal Investigator Andre Witkin, MD
Min Age 50 Years
Gender both
Contact Millie Commodore
More Information


The purpose of this study is to assess the safety and tolerability of the investigational eye drop solution, PAN-90806. The biological response to the eye drops will also be assessed to see if the drug helps slow the progression of neovascular age-related macular degeneration.  Participants (age 50 years and older) enrolled in the study will be randomized into one of three study arms (1 mg/ml BID, 2 mg/ml BID, 4 mg/ml QD).

Study Details

Inclusion Criteria

  • Active, and previously untreated, subfoveal CNV lesions secondary to neovascular macular degeneration
  • Best-corrected visual acuity between 20/63 to 20/160 in the study eye
  • Patient, or patient’s family member, must be willing and able to instill topical ocular drops in the study eye up to two times per day

Exclusion Criteria

  • Additional eye disease in the study eye that would compromise best-corrected visual acuity
  • Best-corrected visual acuity in the fellow eye of worse than 20/320
  • Any prior ocular or systemic treatment or surgery for neovascular macular degneration in the study eye, with the exception of dietary supplements or vitamins

Study Requirements

After participants pass a screening visit, they will be asked to instill investigational eye drops for 8 weeks and come in for a total of 7 visits.

A total of 4 fluorescein angiograms and 4 blood collections will be required for the study